The new line will add capacity to Catalent’s pipeline of clinical programs and commercial launches at the site.
Catalent announced on Sept. 2, 2020 that it is investing $50 million to install a high-speed vial filling line at its Bloomington, IN, facility.
Expected to be operational in April 2021, the new line will add capacity to Catalent’s pipeline of clinical programs and commercial launches at the site, a company press release said. It will also provide capacity to produce up to 80 million vials annually under barrier isolator technology and a peristaltic pump filling mechanism.
This is the third major investment into the Bloomington facility in two years and, by 2021, the site will offer high-speed filling capacity across three vial lines, two syringe lines, and a flexible line capable of filling vials, syringes, or cartridges, the press release said.
“The industry has seen an increased demand for vial filling of biologic drugs, which has been compounded by the accelerated development of vaccine and therapeutic candidates to address the COVID-19 pandemic,” said Mike Riley, region president, Biologics, North America, in the press release. “Catalent’s continued investment in this capacity will allow us to remain flexible and continue to support the growth of our customers’ programs.”
Source: Catalent
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.